Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Mar. 31, 2022

Comprehensive Income (Loss) Note [Text Block]

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss):

Supplemental Equity

The Company has declared cash dividends per share of $0.32 and $0.96 in both the three and nine months ended March 31, 2022 and 2021, respectively.

Consolidated Changes in Equity (amounts in thousands)


	Bio-Techne Shareholders
								Accumulated
				Additional				Other
	Common Stock			Paid-in		Retained		Comprehensive		Noncontrolling
	Shares	Amount		Capital		Earnings		Income(Loss)		Interest		Total
Balances at June 30, 2021	38,955	$	390	$	534,411	$	1,085,461	$	(57,291)	$	8,263	$	1,571,234
Net earnings							69,615				(634)		68,981
Other comprehensive income (loss)									(6,925)		(39)		(6,964)
Share repurchases
Common stock issued for exercise of options	295		3		36,345		(13,481)						22,867
Common stock issued for restricted stock awards	20		0		0		(9,765)						(9,765)
Cash dividends							(12,493)						(12,493)
Stock-based compensation expense					11,396								11,396
Common stock issued to employee stock purchase plan	3		0		1,358								1,358
Employee stock purchase plan expense					341								341
Balances at September 30, 2021	39,273	$	393	$	583,851	$	1,119,337	$	(64,216)	$	7,590	$	1,646,955
Net earnings							80,173				(8,114)		72,059
Other comprehensive income (loss)									4,742		66		4,808
Share repurchases	(89)		(1)				(41,293)						(41,294)
Common stock issued for exercise of options	134		1		18,604								18,605
Common stock issued for restricted stock awards	1												—
Cash dividends							(12,576)						(12,576)
Stock-based compensation expense					13,701								13,701
Common stock issued to employee stock purchase plan					6								6
Employee stock purchase plan expense					267								267
Balances at December 31, 2021	39,319	$	393	$	616,429	$	1,145,641	$	(59,474)	$	(458)	$	1,702,531
Net earnings							60,739				(595)		60,144
Other comprehensive income (loss)									4,329		(1)		4,328
Share repurchases	(145)		(1)				(60,837)						(60,838)
Common stock issued for exercise of options	84		1		10,494								10,495
Common stock issued for restricted stock awards	1						(159)						(159)
Cash dividends							(12,577)						(12,577)
Stock-based compensation expense					8,043								8,043
Common stock issued to employee stock purchase plan	4				1,330								1,330
Employee stock purchase plan expense					25								25
Balances at March 31, 2022	39,263		393		636,321		1,132,807		(55,145)		(1,054)		1,713,322


	Bio-Techne Shareholders
								Accumulated
				Additional				Other
	Common Stock			Paid-in		Retained		Comprehensive		Noncontrolling
	Shares	Amount		Capital		Earnings		Income(Loss)		Interest		Total
Balances at June 30, 2020	38,453	$	385	$	420,536	$	1,057,470	$	(97,199)	$	—	$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards							(276)						(276)
Net earnings							33,395						33,395
Other comprehensive income (loss)									14,057				14,057
Common stock issued for exercise of options	117		1		13,727								13,728
Common stock issued for restricted stock awards	25		0		(0)		(4,890)						(4,890)
Cash dividends							(12,336)						(12,336)
Stock-based compensation expense					12,667								12,667
Common stock issued to employee stock purchase plan	6		0		1,463								1,463
Employee stock purchase plan expense					286								286
Balances at September 30, 2020	38,601	$	386	$	448,679	$	1,073,362	$	(83,142)	$	—	$	1,439,285
Non-controlling interest in Eminence											8,985		8,985
Net earnings							46,274				(130)		46,144
Other comprehensive income (loss)									18,904		83		18,987
Common stock issued for exercise of options	161		2		16,748		(2,482)						14,268
Common stock issued for restricted stock awards	3		0		(0)		0						—
Cash dividends							(12,392)						(12,392)
Stock-based compensation expense					15,471								15,471
Employee stock purchase plan expense					106								106
Balances at December 31, 2020	38,765	$	388	$	481,004	$	1,104,762	$	(64,238)	$	8,938	$	1,530,854
Net earnings							45,782				(380)		45,402
Other comprehensive income (loss)									215		(69)		146
Share repurchases	(120)		(1)				(43,177)						(43,178)
Common stock issued for exercise of options	195		2		21,324		(4,332)						16,994
Common stock issued for restricted stock awards	10		0		(0)		(1,801)						(1,801)
Cash dividends							(12,446)						(12,446)
Stock-based compensation expense					10,232								10,232
Common stock issued to employee stock purchase plan	4		0		1,328								1,328
Employee stock purchase plan expense					411								411
Balances at March 31, 2021	38,854	$	389	$	514,299	$	1,088,788	$	(64,023)	$	8,489	$	1,547,942

Accumulated Other Comprehensive Income

The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The Company reclassified $4.0 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the nine months ended March 31, 2022. The Company reclassified $5.5 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the nine months ended March 31, 2021.

The accumulated balances related to each component of other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows:


	Unrealized
	Gains		Foreign
	(Losses) on		Currency
	Derivative		Translation
	Instruments		Adjustments		Total
Balance as of June 30, 2021	$	(6,193)	$	(51,098)	$	(57,291)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne		7,757		(9,599)		(1,842)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾		3,988	$	—	$	3,988
Balance as of March 31, 2022 ⁽²⁾	$	5,552		(60,697)		(55,145)


	Unrealized
	Gains		Foreign
	(Losses) on		Currency
	Derivative		Translation
	Instruments		Adjustments		Total
Balance as of June 30, 2020 attributable to Bio-Techne	$	(13,253)	$	(83,946)	$	(97,199)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne		(13)		27,686		27,673
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽³⁾		5,503		—		5,503
Balance as of March 31, 2021 ⁽²⁾	$	(7,763)	$	(56,260)	$	(64,023)

⁽¹⁾

Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $5,214 to interest expense and recorded a related tax benefit of $1,226 during the nine months ended March 31, 2022.

⁽²⁾

The Company had a net deferred tax liability of $1,706 and a net deferred tax benefit of $2,394 included in the accumulated other comprehensive income loss as of March 31, 2022 and 2021, respectively.

⁽³⁾

Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,662 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur in the nine months ended March 31, 2021. The Company also recorded a related tax benefit of $1,670 during the nine months ended March 31, 2021.